



## **Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024**

February 12, 2024

STAMFORD, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced the Company will host a conference call and live audio webcast on Monday, March 4, 2024, at 4:30 p.m. EST to report fourth quarter and full year 2023 financial results and provide a corporate update.

To participate in the conference call, please register [here](#). Registrants will receive the dial-in numbers and a unique PIN.

A live audio webcast and archived replay of the call will be available under "Events & Presentations" in the Investors section of the Company's website at [www.CaraTherapeutics.com](http://www.CaraTherapeutics.com).

### **About Cara Therapeutics**

Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company's KORSUVA<sup>®</sup> (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin, with an ongoing Phase 2/3 clinical program for patients with notalgia paresthetica, a neuropathic disorder characterized by chronic pruritus of the upper back for which there are no FDA-approved therapies. For more information, visit [www.CaraTherapeutics.com](http://www.CaraTherapeutics.com) and follow the company on [X \(Twitter\)](#), [LinkedIn](#) and [Instagram](#).

### **MEDIA CONTACT:**

Annie Spinetta  
6 Degrees  
973-768-2170  
[aspinetta@6degreespr.com](mailto:aspinetta@6degreespr.com)

### **INVESTOR CONTACT:**

Iris Francesconi, Ph.D.  
Cara Therapeutics  
203-406-3700  
[investor@caratherapeutics.com](mailto:investor@caratherapeutics.com)



Source: Cara Therapeutics, Inc.